# A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

> **NCT06653153** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 1400 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Remternetug
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06653153
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-24
- **Primary completion:** 2029-04
- **Final completion:** 2030-10
- **Target enrollment:** 1400 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06653153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06653153, "A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06653153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*